Serotonin syndrome induced by administration of venlafaxine and phenelzine.
Heisler
M A
MA
Guidry
J R
JR
Arnecke
B
B
D000928:Antidepressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002493:Central Nervous System Diseases / Q000139:chemically induced* / Q000503:physiopathology; D003511:Cyclohexanols / Q000009:adverse effects* / Q000627:therapeutic use; D003866:Depressive Disorder / Q000188:drug therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D010624:Phenelzine / Q000009:adverse effects* / Q000627:therapeutic use; D012701:Serotonin / Q000502:physiology; D018490:Serotonin Agents / Q000009:adverse effects*; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D013577:Syndrome; D000069470:Venlafaxine Hydrochloride
D000928:Antidepressive Agents; D003511:Cyclohexanols; D010624:Phenelzine; D012701:Serotonin; D018490:Serotonin Agents; D017367:Selective Serotonin Reuptake Inhibitors; D000069470:Venlafaxine Hydrochloride